Trade Idea: ATNM

07/13/17

Hello!

We are continuing to monitor our newest trade opportunity, ATNM.

We alerted the trade idea Monday afternoon around 0.98. Thus far ATNM has traded as high as 1.26 (for only a few seconds), but has repeatedly hit a high of 1.09, upside of 11% from our alert, over the past few days, including today.

This morning ATNM released breaking news that has thus far once again propelled ATNM to a day high of 1.09.

In the event that ATNM is able to break above 1.09 there exists the opportunity for it to test its 20 and 200 day moving averages.

ATNM has a 20 day moving average of 1.15 And a 200 day moving average of 1.24, upside of 13%.

ATNM continues to demonstrate a potentially undervalued RSI of 34 on the daily chart.

For your convenience here is the news ATNM announced this morning:

Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET

NEW YORK, July 13, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options will hold a webinar focused on  its Actimab-A program and recent developments related to CD33 targeted Acute Myeloid Leukemia (AML) therapies.  Until this year, Mylotarg, which targets CD33, was the only drug approved for the treatment of AML in several decades.  The drug was withdrawn from the market and the sponsor (Pfizer) recently resubmitted BLA to the FDA and an FDA Advisory Committee Meeting was held on July 11, 2017.  The CD33 antigen is a validated target that is the focus of drug development programs from several companies using different antibody based approaches including; naked antibodies (Boehringer Ingelheim), bispecific (Amgen, Johnson and Johnson/Amphivena), antibody drug conjugates (Immunogen, Pfizer, and, until recently, Seattle Genetics) and radioimmunotherapy (Actinium and Bayer).

Sandesh Seth, Actinium’s Chairman and CEO said, “Recent events related to CD33 targeted AML therapies including Mylotarg’s ODAC FDA panel have furthered our belief that Actimab-A has the potential to be a best in class asset. Our radioisotope labeled antibody approach, which has demonstrated compelling safety and efficacy results in over 100 patients to date in multiple studies, is currently progressing in a Phase 2 trial for older patients with AML who are ineligible for induction chemotherapy. This is a patient population with significant unmet medical needs that have been unaddressed by other CD33 targeting technological approaches. We are excited to conduct this webinar in light of recent developments pertaining to Actimab-A, which we have tremendous excitement given recent events related to other CD33 targeting development programs.”

Source: Yahoo Finance

We are continuing to monitor ATNM.

You need to evaluate the chart in real-time and establish for yourself whether it is an appropriate trade opportunity for you or not.​​​​​​​

If you are not familiar with my trading guidelines, please read them below.

These trading guidelines are designed to give you a starting point to develop your own personal trading philosophy and approach.

Since every traders/investors circumstance is different, make sure you create a personalized approach that works for you and always consult a financial adviser (not me).

Happy Trading!


 

Good Morning!

As a reminder, we are monitoring our new trade opportunity,  ATNM.

After experiencing a low earlier in the day yesterday, ATNM closed the trading session near the high of day at 0.98, a potentially bullish indicator.

So far in premarket trading ATNM hit a high of 1.26, upside of 28%. Currently ATNM is trading at 1.09, upside of 11% from our alert.

ATNM has a 20 day moving average of 1.17 and a 200 day moving average of 1.25.

We believe ATNM may offer further upside potential. As always, follow your trading rules.

For your convenience we have included our initial report below.

 


 

Good Afternoon!

I hope you have been well.

As you may have noticed we have not alerted many trade ideas over the summer.

We have been looking for what could potentially be deeply oversold opportunities rather than chasing plays to the upside as the Dow Jones Industrial Average continues hitting all time highs.

Here is a trade idea we believe could present you with increased upside opportunity…

 

Trade Idea:  Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

 

Highlights:

  • ATNM could potentially be extremely oversold after falling as much as 9% today.
  • The last time ATNM traded near these levels was in late 2016 and early 2017 after which the company rallied to a high of 1.72 for upside of more than 60%.
  • ATNM witnessed a considerable increase in volume earlier today, which could potentially indicate an area of support .
  • If ATNM is able to sustain today’s low of 0.90, this could potentially present you with increased upside opportunity.
  • ATNM has a RSI of 20 on the daily chart, potentially suggesting increased undervaluation in the short-term.
  • ATNM has a 20 day moving average at 1.18, 31% above today’s low of 0.90 presenting you with an increased upside opportunity.
  • In the past few weeks ATNM has reported a number of breaking developments that may have been overlooked by Wall Street.

Recent News:

Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET

NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options will hold a webinar focused on  its Actimab-A program and recent developments related to CD33 targeted Acute Myeloid Leukemia (AML) therapies.  Until this year, Mylotarg, which targets CD33, was the only drug approved for the treatment of AML in several decades.  The drug was withdrawn from the market and the sponsor (Pfizer) recently resubmitted BLA to the FDA and an FDA Advisory Committee Meeting will be held on July 11, 2017.  The CD33 antigen is a validated target that is the focus of drug development programs from several companies using different antibody based approaches including; naked antibodies (Boehringer Ingelheim), bispecific (Amgen, Johnson and Johnson/Amphivena), antibody drug conjugates (Immunogen, Pfizer, and, until recently, Seattle Genetics) and radioimmunotherapy (Actinium and Bayer).

Dr. Mark Berger, Actinium’s Chief Medical Officer said, “Having led the original approval of a CD33 targeting therapy in AML, I know firsthand that CD33 is an excellent target given its high expression rates in AML and specificity for hematologic cells.  Several recent events in the CD33 AML field bolster our belief that Actimab-A, which outside of Mylotarg is the most advanced development program targeting CD33, has the potential to be a best in class asset.  While several technological approaches are being studied, we believe that our actinium-225 radioisotope approach may be most beneficial to patients based on the promising efficacy and safety profile that has been demonstrated in multiple clinical trials to date.  In addition, we look forward to providing an update on the Actimab-A phase 2 trial which is on track for interim results later this year in light of these developments.”

 

About ATNM:

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options.

Actinium’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. 

The Company’s lead product candidate, Iomab-B, is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.  A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. 

Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates.  The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. 

The Company’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over.

 Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. 

In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial.

Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.

Source: Trading View, Yahoo Finance

You need to evaluate the chart in real-time and establish for yourself whether it is an appropriate trade opportunity for you or not.​​​​​​​

If you are not familiar with my trading guidelines, please read them below.

These trading guidelines are designed to give you a starting point to develop your own personal trading philosophy and approach.

Since every traders/investors circumstance is different, make sure you create a personalized approach that works for you and always consult a financial adviser (not me).

Happy Trading!

Ultimate Stock Alerts 

—————————————————

Trading Rules [Please Review Before Taking Any Action]:

  1. Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb – if you cannot sleep at night as a consequence of your investment, then you have over invested.
  2. Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
  3. Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use “trailing stop %” or “trailing stop limit” orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
  4. Cut losses quickly when day/swing trading. It’s better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
  5. Actively manage all your investments & trade during market hours only. Trading during pre/post market hours carries greater volatility/risk.

DISCLAIMER

This report/release is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our reports/releases unless you can afford to lose your entire investment. The track record, gains, upside or losses are all hypothetical and should not be considered as a basis for investment.

This report/release is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reports/releases distributed through disseminated reports/released are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov;the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in our disseminated reports/releases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated report/release or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned herein.

We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.

The purpose of this report/release, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of UltimateStockAlerts.com have been compensated thirty thousand dollars cash via bankwire, earned upon receipt, for distribution of our opinions and publicly available information for ATNM from Sunrise Media on 07/11/17. Owners and operators of UltimateStockAlerts.com have been previously compensated thirty five thousand dollars cash via bank wire, earned upon receipt, for distribution of our opinions and publicly available information for ATNM from Sunrise Media on 4/5/17. Owners and operators of UltimateStockAlerts.com have been previously compensated thirty thousand dollars cash via bank wire, earned upon receipt, for distribution of our opinions and publicly available information for ATNM from Third Coast Media. Owners and operators of UltimateStockAlerts.com have been previously compensated thirty thousand dollars cash via bank wire, earned upon receipt, for distribution of our opinions and publicly available information for ATNM from Small Cap Specialists. Owners and operators of UltimateStockAlerts.com do not own any equity nor debt in ATNM as of 7/13/17. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated reports/releases does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Owners and operators of UltimateStockAlerts.com own several newsletters, therefore you may receive our emails featuring companies at different times.

You are receiving this report/release because you subscribed to received it at our website or through a third party site.  All of our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@ultimatestockalerts.com to change your information at any time.  By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer which can be read at any time at www.UltimateStockAlerts.com/Disclaimer.

Full disclaimer can be read at www.UltimateStockAlerts.com/Disclaimer.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

Leave a Reply

Your email address will not be published. Required fields are marked *

bonus

Free Guide To Become A Successful Trader/Investor

lock We Never Sell Or Share Your Email

No Hidden Fees. Unsubscribe Anytime.